Financial analysis on June 8, 2026, designated Green Thumb Industries as a strong buy. The company is positioned to benefit from the federal rescheduling of cannabis to a Schedule III drug.
The move eliminates the 280E federal tax burden for state-licensed medical cannabis operations. This allows the company to deduct standard corporate expenses for the first time. Analysts expect this change to significantly expand net margins and improve cash flow.
Green Thumb reported $344.5 million in cash at the end of the first quarter. The company maintains a strong balance sheet and an active share repurchase program. These factors position the firm to lead the ongoing institutionalization of the U.S. cannabis market.